Introduction
Nivolumab in R/M SCCHN After Platinum Therapy
•
The prognosis for patients with platinum-refractory R/M squamous cell
carcinoma of the head and neck (SCCHN) is extremely poor
– Median overall survival (OS) is ≤ 6 months
– Anticancer agents have been ineffective at increasing OS
•
New treatments are needed to improve survival for this patient
population
•
SCCHN can evade host cellular immune response by expression of T
cell suppressive ligands, such as PD-L1, for the immune checkpoint
programmed death-1 (PD-1) receptor
1,2
•
PD-L1 is frequently expressed on both HPV-positive and HPV-
negative SCCHN
3,4
18
1.
Ferris RL, et al.
J Clin Oncol
. 2015;33:3293–3304;
2.
Topalian SL, et al.
Cancer Cell.
2015;27:450-461;
3.
Badoual C, et al.
Cancer Res
. 2013;73:128–138;
4.
Concha-Benavente F, et al.
Cancer Res
. 2016;76:1031–1043.
